As reported in a recent publication (access here), ASAPprime® was successfully used by pharmaceutical scientists at Roche-Genentech to justify filing with reduced long-term stability data for a Supplemental New Drug Application (sNDA). The filing relied on the accuracy shown by the ASAPprime® stability predictions matching limited long-term stability data to successfully argue for a longer shelf life assignment.